Skip to main content

Advertisement

Table 2 Baseline clinicopathologic characteristics of patients with second-line treatment

From: Right- and left-sided colorectal cancers respond differently to cetuximab

Clinicopathologic characteristic   Cetuximab group   Chemotherapy alone group P valuec
   All patients RSCC LSCRC P value   All patients RSCC LSCRC P value
No. of patients   96 28 68   93 44 49 0.011*
Median age at diagnosis            
    ≤65 years   82 (85.4) 21 (75.0) 61 (89.7) 0.108   72 (77.4) 30 (68.2) 42 (85.7) 0.051 0.191
    >65 years   14 (14.6) 7 (25.0) 7 (10.3)    21 (22.6) 14 (31.8) 7 (14.3)   
Sex      0.488      1.000 0.105
    Male   63 (65.6) 20 (71.4) 43 (63.2)    50 (53.8) 24 (54.5) 26 (53.1)   
    Female   33 (34.4) 8 (28.6) 25 (36.8)    43 (46.2) 20 (45.5) 23 (46.9)   
ECOG performance status      0.074      0.438 0.310
    0   53 (55.2) 13 (46.4) 40 (58.8)    41 (44.0) 19 (43.2) 22 (44.9)   
    1   35 (36.5) 11 (39.3) 24 (35.3)    42 (45.2) 22 (50.0) 20 (40.8)   
    ≥2   8 (8.3) 4 (14.3) 4 (5.9)    10 (10.8) 3 (6.8) 7 (14.3)   
Pathology      0.102      0.183 0.822
    Adenocarcinoma   84 (87.5) 22 (78.6) 62 (91.2)    83 (89.2) 37 (84.1) 46 (93.9)   
    Mucinous & signet-ring cell   12 (12.5) 6 (21.4) 6 (8.8)    10 (10.8) 7 (15.9) 3 (6.1)   
Metastasis      0.804      1.000 0.005*
    Single   69 (71.9) 21 (75.0) 48 (70.6)    48 (51.6) 23 (52.3) 25 (51.0)   
    Multiple   27 (28.1) 7 (25.0) 20 (29.4)    45 (48.4) 21 (47.7) 24 (49.0)   
Metastasis resection   24 (25.0) 6 (21.4) 18 (26.5) 0.796   16 (17.2) 11 (25.0) 15 (30.6) 0.646 0.215
Total cycles of cetuximab (median)   5 (2-20) 4 (2-13) 5 (2-20) 0.272  
Total cycles of chemotherapy (median)   8 (2-66) 7 (4-35) 8 (2-66) 0.548   6 (2-36) 6 (2-36) 6 (2-27) 1.000 0.031*
All three active drugsa   87 (90.6) 24 (85.7) 63 (92.6) 0.441   84 (90.3) 39 (88.6) 45 (91.8) 0.731 1.000
Backbone chemotherapy      0.139      1.000 0.745
    Oxaliplatin-based   27 (28.1) 11 (39.3) 16 (23.5)    24 (25.8) 11 (25.0) 13 (26.5)   
    Irinotecan-based   69 (71.9) 17 (60.7) 52 (76.5)    69 (74.2) 33 (75.0) 36 (73.5)   
Bevacizumab during the disease   27 (28.1) 11 (39.3) 16 (23.5) 0.637   22 (23.7) 8 (18.2) 14 (28.6) 0.329 0.510
Recurrent diseaseb   42 (43.8) 6 (21.4) 36 (52.9) 0.006*   33 (35.5) 19 (43.2) 14 (28.6) 0.199 0.298
  1. All values are presented as the number of patients followed by percentages in parentheses. a Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the course of their disease. b Patients who had metastatic disease after curative-intent primary tumor resection. c Patient characteristics were compared between the cetuximab and chemotherapy groups. Other footnotes as in Table 1